Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 207.90 INR
Change Today +5.60 / 2.77%
Volume 161.8K
CLAR On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:26 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

claris lifesciences ltd (CLAR) Snapshot

Open
206.00
Previous Close
202.30
Day High
213.60
Day Low
206.00
52 Week High
04/13/15 - 358.00
52 Week Low
10/22/14 - 163.10
Market Cap
11.3B
Average Volume 10 Days
85.5K
EPS TTM
23.58
Shares Outstanding
54.6M
EX-Date
01/20/14
P/E TM
8.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for CLARIS LIFESCIENCES LTD (CLAR)

Related News

No related news articles were found.

claris lifesciences ltd (CLAR) Related Businessweek News

No Related Businessweek News Found

claris lifesciences ltd (CLAR) Details

Claris Lifesciences Limited, together with its subsidiaries, manufactures and sells drugs and pharmaceuticals worldwide. The company manufactures and markets products for anesthesia and analgesia, blood products, plasma volume expanders, anti-infectives, and oncology segments. It also provides dialysis and transplant range across systems, solutions, medicines, disposables, and equipment. In addition, the company offers injectables for various therapeutic groups, including anti-emetics, CNS, cardiology, anti-malaria, haematinics, etc. It offers its products through various delivery systems, such as glass and plastic bottles, ampoules, and non-PVC/PVC bags. The company primarily serves government and private hospitals, aid agencies, and nursing homes. Claris Lifesciences Limited was incorporated in 1994 and is headquartered in Ahmedabad, India.

Founded in 1994

claris lifesciences ltd (CLAR) Top Compensated Officers

Vice Chairman, Managing Director, Member of S...
Total Annual Compensation: 26.5M
Chief Financial Officer, Whole Time Director,...
Total Annual Compensation: 9.4M
Compliance Officer, Senior Vice President and...
Total Annual Compensation: 6.7M
Whole Time Director, Member of Share Transfer...
Total Annual Compensation: 5.8M
Compensation as of Fiscal Year 2015.

claris lifesciences ltd (CLAR) Key Developments

Claris Lifesciences Limited Reports Unaudited Consolidated and Standalone Earnings Results for the First Quarter Ended June 30, 2015

Claris Lifesciences Limited reported unaudited consolidated and standalone earnings results for the first quarter ended June 30, 2015. For the quarter, the consolidated company's net sales/income from operations (net of excise duty) was INR 1,865.148 million against INR 1,510.513 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 387.291 million against INR 180.681 million a year ago. Profit from ordinary activities before tax was INR 370.855 million against INR 220.277 million a year ago. Net profit for the period was INR 223.267 million against INR 160.669 million a year ago. Basic and diluted before & after extraordinary items earnings of INR 10 per each (Not annualized) was INR 3.72 against INR 2.53 a year ago. EBITDA was INR 576.86 million against INR 414.36 million a year ago. For the quarter, the standalone company's net sales/income from operations (Net of excise duty) was INR 1,373.944 million against INR 1,375.356 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 16.967 million against profit of INR 147.602 million a year ago. Profit from ordinary activities before tax was INR 83.281 million against INR 195.085 million a year ago. Net profit for the period was INR 64.178 million against INR 136.005 million a year ago. Basic and diluted before & after extraordinary items earnings of INR 10 per each (Not annualized) was INR 1.18 against INR 2.22 a year ago.

Claris Lifesciences Limited, Board Meeting, Aug 06, 2015

Claris Lifesciences Limited, Board Meeting, Aug 06, 2015. Agenda: To consider quarterly results.

Claris Lifesciences Limited Reports Audited Consolidated and Standalone Earnings Results for the Quarter and Fifteen Months Ended March 31, 2015

Claris Lifesciences Limited reported audited consolidated and standalone earnings results for the quarter and fifteen months ended March 31, 2015. For the quarter, on consolidated basis, net sales /income from operations was INR 1,547.280 million compared to INR 1,330.917 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 146.275 million compared to INR 88.243 million a year ago. Profit from ordinary activities before tax was INR 179.524 million against INR 191.976 million a year ago. Net profit was INR 125.015 million or INR 1.91 per basic and diluted share before and after extraordinary items compared to net profit of INR 154.126 million or INR 2.09 per basic and diluted share before and after extraordinary items a year ago. For the fifteen months, on consolidated basis, net sales /income from operations was INR 7,801.130 million compared to INR 6,583.755 million as of December 31, 2014. Profit from operations before other income finance cost and exceptional items was INR 1,064.250 million compared to INR 1,011.811 million as of December 31, 2014. Profit from ordinary activities before tax was INR 1,444.681 million against INR 1,074.855 million as of December 31, 2014. Net profit was INR 1,566.717 million or INR 25.89 per basic and diluted share before and after extraordinary items compared to net profit of INR 854.084 million or INR 13.23 per basic and diluted share before and after extraordinary items as of December 31, 2014. For the quarter, on standalone basis, net sales /income from operations was INR 1,307.543 million compared to INR 1,249.777 million a year ago. Loss from operations before other income finance cost and exceptional items was INR 142.022 million compared to profit INR 110.435 million a year ago. Profit from ordinary activities before tax was INR 42.307 million against INR 203.229 million a year ago. Net profit was INR 38.442 million or INR 0.70 per basic and diluted share before and after extraordinary items compared to net profit of INR 165.710 million or INR 2.60 per basic and diluted share before and after extraordinary items a year ago. For the six months, on standalone basis, net sales /income from operations was INR 7,022.216 million compared to INR 6,287.935 million as of December 31, 2014. Profit from operations before other income finance cost and exceptional items was INR 567.775 million compared to INR 969.031 million as of December 31, 2014. Profit from ordinary activities before tax was INR 1,072.190 million against INR 1,032.086 million as of December 31, 2014. Net profit was INR 1,386.896 million or INR 24.02 per basic and diluted share before and after extraordinary items compared to net profit of INR 812.185 million or INR 12.73 per basic and diluted share before and after extraordinary items as of December 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLAR:IN 207.90 INR +5.60

CLAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLAR.
View Industry Companies
 

Industry Analysis

CLAR

Industry Average

Valuation CLAR Industry Range
Price/Earnings 7.8x
Price/Sales 1.5x
Price/Book 0.8x
Price/Cash Flow 6.0x
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLARIS LIFESCIENCES LTD, please visit www.clarislifesciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.